UniProt P16591 · PDB · AlphaFold · Substrate: pEY · Clone: aa540-822high-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ceritinib | 98.4% | 1.6% | 95.44 | 0.618 |
| 2 | Brigatinib | 98.2% | 1.8% | 82.96 | 0.513 |
| 3 | Lorlatinib | 98.1% | 1.9% | 97.24 | 0.694 |
| 4 | Lazertinib | 97.7% | 2.3% | 97.47 | 0.674 |
| 5 | Repotrectinib | 96.6% | 3.4% | 84.21 | 0.608 |
| 6 | Crizotinib | 94.0% | 6.0% | 91.39 | 0.581 |
| 7 | Entrectinib | 91.5% | 8.5% | 93.69 | 0.671 |
| 8 | Gilteritinib | 91.0% | 9.0% | 88.97 | 0.506 |
| 9 | Pacritinib | 90.4% | 9.6% | 88.64 | 0.452 |
| 10 | Defactinib | 84.7% | 15.3% | 92.68 | 0.450 |
| 11 | Nintedanib | 83.8% | 16.2% | 90.23 | 0.608 |
| 12 | Neratinib | 79.4% | 20.6% | 93.18 | 0.597 |
| 13 | Alectinib | 72.7% | 27.3% | 95.49 | 0.651 |
| 14 | Fostamatinib | 69.2% | 30.8% | 96.74 | 0.613 |
| 15 | Sunitinib | 57.3% | 42.7% | 91.73 | 0.524 |
| 16 | Bosutinib | 53.6% | 46.4% | 87.22 | 0.555 |
| 17 | Ponatinib | 50.9% | 49.1% | 78.23 | 0.534 |
| 18 | Pralsetinib | 44.7% | 55.3% | 93.43 | 0.643 |
| 19 | Fedratinib | 36.5% | 63.5% | 96.21 | 0.576 |
| 20 | Midostaurin | 35.8% | 64.2% | 78.64 | 0.500 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 2.71
- Epithelial log2(TPM+1): 1.99
- Fold change: 0.71
- Status: No significant change
High-confidence drugs
- Lazertinib — inh 97.7% · KISS 53.32
- Lorlatinib — inh 98.1% · KISS 49.51
- Ceritinib — inh 98.4% · KISS 45.00
Selectivity landscape vs inhibition on FER
Each point is one of the 92 approved drugs; color = inhibition % on FER.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…